Stockwinners Market Radar for October 11, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:22 EDT Cathie Wood's ARK Investment bought 619K shares of PacBio today

20:20 EDT Cathie Wood's ARK Investment bought 2.05M shares of Ginkgo Bioworks today

20:11 EDT Zscaler director sells $1.22M in common stock - In a regulatory filing, Zscaler disclosed that its director Amit Sinha sold 7.4K shares of common stock on October 9th in a total transaction size of $1.22M.

18:43 EDT UAW confirms strike at Ford's Kentucky Truck Plant - In an unannounced move, 8,700 UAW members walked off the job today at 6:30 p.m. ET, shutting down Ford Motor Company's (F) Kentucky Truck Plant in Louisville. The strike was called after Ford refused to make further movement in bargaining. The surprise move marks a new phase in the UAW's Stand Up Strike. Previous expansions of the strike occurred at a deadline set in advance by the union. The move comes one day before the four-week mark since contracts expired at Ford, General Motors (GM), and Stellantis (STLA). "We have been crystal clear, and we have waited long enough, but Ford has not gotten the message," said UAW President Shawn Fain. "It's time for a fair contract at Ford and the rest of the Big Three. If they can't understand that after four weeks, the 8,700 workers shutting down this extremely profitable plant will help them understand it." Local 862 members at Kentucky Truck Plant make the Ford Super Duty pickups as well as the Ford Expedition and the Lincoln Navigator.

18:40 EDT Centrus Energy begins uranium enrichment operations in Ohio - Centrus Energy has begun enrichment operations at its High-Assay Low-Enriched Uranium - HALEU - facility in Piketon, Ohio, and expects to begin withdrawing HALEU product later this month. It is the only NRC-licensed HALEU facility in the U.S. and the first new U.S.-owned, U.S.-technology uranium enrichment plant to begin production since 1954. HALEU is an advanced nuclear fuel required for most of the next-generation reactor designs currently under development. The capacity of the 16-centrifuge cascade is about 900 kilograms of HALEU per year, but with sufficient funding and offtake commitments, Centrus could expand production.

17:57 EDT Momentus in contract with RIDE! Space for transportation, orbital services in Q1 - Momentus has signed a contract with RIDE! Space for transportation and orbital delivery services in the first quarter of 2024. RIDE! Space will be flying its Gaindesat and Djibouti payloads on a single mission. "We are thrilled to mark this historic moment for the space sector of Africa with Momentus," said RIDE! Space Chief Executive Officer Valentin Benoit. "Being an actor for sending the 1st Senegalese satellite and the 2nd one for Djibouti proves the objective RIDE! has given itself: make space more convenient, affordable and reliable. In this mission, Momentus plays a key role. They have also always been a trusted partner to RIDE!, responsive and ready to accommodate small sat players from our ecosystem." "The African Space Industry Annual Report released in August reports that the African space economy is projected to grow to more than $22B by 2026," said Momentus Chief Commercial Officer Chris Kinman. "We anticipate rideshare services to be an important enabler for this growth. We're looking forward to working with RIDE! Space as they support access to Low-Earth Orbit for new and established African customers." In addition to rideshare missions, Momentus offers Delta-V delivery for missions requiring precise custom orbits. The Company also provides hosted payload services and its M-1000 satellite bus for customized and dedicated missions.

17:50 EDT Minim Inc trading resumes

17:35 EDT Bsquare Corp trading resumes

17:28 EDT Costco EVP Frates sells 1,200 common shares - In a regulatory filing, Costco executive VP Caton Frates disclosed the sale of 1,200 common shares of the company on October 6 at a price of $562.6418 per share.

17:20 EDT National Interstate to replace iTeos in S&P 600 at open on 10/18 - NCR Atleos Corp. (NATL) will replace iTeos Therapeutics (ITOS) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 18. S&P MidCap 400 constituent NCR Corp. (NCR) is spinning off NCR Atleos in a transaction expected to be completed on October 17. Following the spin-off, the NCR parent will have a name and symbol change to NCR Voyix Corp. (VYX) and will remain in the S&P MidCap 400. iTeos Therapeutics is no longer representative of the small-cap market space.

17:14 EDT Astria Therapeutics to pay $15M upfront license fee - Under the terms of the license agreement, Astria will pay Ichnos a one-time upfront license fee of $15M. Astria is also obligated to pay Ichnos up to $305M in milestones, of which up to $20M are clinical development milestones in up to three indications and $285M are related to regulatory approval and commercial sales milestones for all licensed products in up to three indications. In addition, Ichnos will be eligible to receive tiered mid-single digit to low-double digit royalties based on Astria's and any of its affiliates' or sublicensees' annual net sales of the licensed products, subject to reduction in specified circumstances.

17:08 EDT Osisko Gold reports Q3 royalty and streams revenue C$62.1M - Osisko Gold provided an update on Q3 deliveries, revenues, cash margin and asset advancements. Osisko earned approximately 23,292 attributable gold equivalent ounces in Q3, including 1,386 GEOs earned from the recently acquired CSA silver stream. Recorded preliminary revenues from royalties and streams of C$62.1M during Q3, and preliminary cost of sales of C$4.4M, resulting in a record quarterly cash margin of approximately C$57.7M, or 93%. Osisko's cash balance was relatively stable at the end of Q3 at approximately C$70.8M, resulting in a net debt position of approximately C$244.6M as at September 30, representing an improvement of $5.0M despite additional investments in royalties completed during the quarter. Paul Martin, Interim CEO, commented: "Osisko delivered a solid quarter of GEOs earned, along with record revenues and cash margin in Q3 despite challenges faced by some of our key operating partners over the past several months....While we anticipate improved quarter-over-quarter performance at several of our core producing assets, Renard will continue to be impacted by weak rough diamond prices and, as a result, Osisko is assuming no reportable GEOs from Renard in Q4. As such, we now are guiding towards the low end of our GEO delivery guidance for 2023."

17:02 EDT Empire Petroleum commences 2023 drilling program - Empire Petroleum announced the formal commencement of its 2023 drilling program with the recent spud of a new well at its North Dakota asset, the "Starbuck" Field. A pilot drilling program on Empire's New Mexico assets is expected to begin in 2024. Additional specifics concerning the Starbuck drilling program include: 10-14 drilled wells; average lateral length per well of approximately 2,300 feet in Phase 1, with a 5,900-foot length in Phase 2; average capital spend per well of $1.6M-$1.8M; and total capital spending for the program of $20M-$22M. Starbuck surface facilities are nearing completion and ready to bring additional production online in Q4.

17:00 EDT Genetron Holdings Ltd - ADR trading resumes

16:47 EDT IPG Photonics announces passing of COO Felix Stukalin - In a regulatory filing, IPG Photonics disclosed that Felix Stukalin, the company's Senior Vice President, COO and member of the company's Board of Directors, passed away on October 6, 2023. He will be greatly missed and the company extends its sincere condolences to Stukalin's family.

16:33 EDT Victoria's Secret says October positioned to be best month of Q3 - Commenting on third quarter results to date, the company mentioned, "Our sales growth internationally has been ahead of plan and our sales trends in North America continue to improve each month as planned: August was better than second quarter, September was better than August, and our early October results have positioned us for our best month of the third quarter. This is consistent with our expectations and encouraging as we finalize our plans for the all-important holiday season and fourth quarter selling."

16:31 EDT MSC Industrial increases regular quarterly dividend 5% to 83c per share - MSC Industrial has declared a cash dividend of 83c per share, representing a 5% increase from the previous regular quarterly dividend of 79c per share. The 83c dividend is payable on November 28 to shareholders of record at the close of business on November 14. The ex-dividend date is November 13.

16:30 EDT Neogen CFO buys $150K in common stock - In a regulatory filing, Neogen disclosed that its CFO David Naemura bought 10K shares of common stock on October 11th in a total transaction size of $150.3K. Shares of Neogen are up 1.5% afterhours at $15.20.

16:26 EDT Vital Energy Q3 production averaged approximately 101.3 MBOE/d - Vital Energy provided select preliminary results for third-quarter 2023, including average daily total and oil production and incurred capital investments. Details for the Company's third-quarter 2023 earnings release and conference call are provided within this release. Third-Quarter Production. The Company's third-quarter 2023 total production averaged approximately 101.3 thousand barrels of oil equivalent per day MBOE/d , above guidance of 94.0 - 98.0 MBOE/d. Oil production for the quarter averaged approximately 48.7 thousand barrels of oil per day MBO/d , above guidance of 45.5 - 48.5 MBO/d. Production results were primarily driven by outperformance of recently turned-in-line wells on the Driftwood and Forge acquisitions and in Howard County. Capital Investments. Total incurred capital expenditures during third-quarter 2023 were approximately $162M , excluding non-budgeted acquisitions and leasehold expenditures, below the low end of guidance of $165 - $180M .

16:23 EDT Indivior enters exclusive licensing agreement with Alar Pharmaceuticals - Indivior has gained exclusive global rights to develop, manufacture, and commercialize Alar Pharmaceuticals' portfolio of long-acting injectable formulations that release a prodrug1 of buprenorphine at varying durations, including its lead long-acting injectable candidate, ALA-1000. ALA-1000 is a sustained-release LAI prodrug of buprenorphine. With dosage intervals of potentially up to four times per year, ALA-1000 could address unmet opioid use disorder patient needs with a longer duration of treatment. Indivior will pay $10M to secure exclusive global rights - except in China, Hong Kong, Taiwan and Macau - to develop, manufacture and commercialize ALA-1000 and Alar's future buprenorphine-based LAI product candidates. The payment is in addition to an initial $5M option payment made by Indivior to Alar in Q1. Alar is entitled to potential milestone payments if various developmental, regulatory, and commercial goals are achieved. Alar has been granted composition of matter and formulation patents for ALA-1000 covering sustained-release buprenorphine formulations with expiry in 2037 and 2039. Based in Taichung, Taiwan, Alar is a drug development company which focuses on developing long-acting drug products for central nervous system disorders and chronic diseases. The transaction is not expected to have a material impact on the Group's FY 2023 adjusted results.

16:20 EDT Ventyx Biosciences director Subramaniam sells nearly 50,000 common shares - In a regulatory filing, Ventyx Biosciences director Somu Subramaniam disclosed the sale of 49,152 common shares of the company on October 9 at a price of $30.0264 per share.

16:16 EDT Ross Stores names Stephen Brinkley as President of Operations - Ross Stores announced that Stephen Brinkley, 50, has been named to the newly-created position of President, Operations with an expected start date of October 30, 2023. In his new role, Mr. Brinkley will report to Michael Hartshorn, Group President and Chief Operating Officer. His responsibilities will include Property Development, Stores, and Supply Chain. The Company's Finance, Human Resources, Legal, Marketing, Strategy, and Technology organizations will continue to report directly to Mr. Hartshorn.

16:09 EDT The Oncology Institute appoints Jeremy Castle COO - The Oncology Institute has announced the appointment of Jeremy Castle, MBA, as Chief Operations Officer, effective September 5, 2023. In this role, Mr. Castle leads enterprise field and central operations, pharmacy, real estate, and practice integration, playing a key role in driving TOI's success as a public company. Castle joins TOI with over 15 years of oncology industry experience, and has a track record of driving growth and profitability for multi-state physician groups. He has had other senior leadership positions, including Mr. Castle having previously served as the Chief Operating Officer for United Urology Group and Executive Director for The US Oncology Network.

16:00 EDT Primoris awarded solar project with estimated value of $230M - Primoris Services announced it received solar project awards with a combined value of approximately $230 million. The contracts were secured by the Company's Energy Segment in the third quarter of 2023. The awards are for the engineering, procurement and construction of three utility-scale solar facilities located in the Southwest. Initial construction for all projects will begin in the fourth quarter of 2023 with completion of the projects expected in the second half of 2024.

14:32 EDT Goldman Sachs announces sale of GreenSky to Sixth Street-led consortium - Goldman Sachs Group announced that it has entered into an agreement to sell the GreenSky platform and associated loan assets to a consortium of institutional investors led by Sixth Street. The transaction is expected to close in the first quarter of 2024, subject to standard closing conditions. The transaction is expected to result in a (19c) earnings per share impact on Goldman Sachs' third quarter 2023 results. Until closing, Goldman Sachs will continue to operate the platform and record ongoing business results, including the impact of an agreement for the consortium to purchase newly originated loans. "This transaction demonstrates our continued progress in narrowing the focus of our consumer business. While GreenSky is an attractive business, we are focused on advancing the strategy we laid out for our two core franchises. In Global Banking & Markets, we've improved our wallet share and are demonstrating strong growth in financing activities; and across our Asset & Wealth Management platform we are making very strong progress towards both our fundraising and management fee targets," said David Solomon, Chairman and CEO of Goldman Sachs.

14:20 EDT J&J reports 510(k) clearance from FDA for TriLEAP System - Johnson & Johnson MedTech announced that DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, has received 510(k) clearance from the U.S. Food and Drug Administration for its TriLEAP Lower Extremity Anatomic Plating System, a comprehensive yet modular, procedure-specific system designed to meet the complex needs of orthopaedic surgeons, doctors of podiatric medicine, and foot and ankle specialists. "The TriLEAP System provides a diverse offering of contoured and conventional plates that can accommodate multiple screw diameters, and instruments that can be used during the reduction, internal fixation and fusion of bones and bone fragments," the company stated. Reference Link

13:58 EDT Sony says PS5 cloud streaming launches this month for PS Plus Premium users - Sony's PlayStation unit provided more details about PS5 cloud streaming for PlayStation Plus Premium members. "Starting this month, we will begin launching cloud streaming access for supported PS5 digital titles within the PlayStation Plus Game Catalog and Game Trials, as well as supported titles in the PS5 game library that PlayStation Plus Premium members own," the company said. "Select PS5 games will be available for streaming, and we're planning to have hundreds of PS5 titles to support this new benefit." Such benefits include: top PS5 hits from the PlayStation Plus Game Catalog, such as "Marvel's Spider-Man: Miles Morales," "Horizon Forbidden West," "Ghost of Tsushima," "Mortal Kombat 11," and "Saints Row IV"; Game Trials for PS5 games, such as "Hogwarts Legacy," "The Witcher 3: Wild Hunt," and "The Calisto Protocol," and; Additional PS5 digital titles PlayStation Plus Premium members own that will be available for streaming, such as "Resident Evil 4," "Dead Island 2," "Genshin Impact," "Fall Guys," and "Fortnite." The service is targeting an October 17 launch in Japan, October 23 launch in Europe, and October 30 launch in North America. Reference Link

13:50 EDT Ericsson names Chris Houghton COO - Ericsson announced the appointment of Chris Houghton to Chief Operating Officer and Asa Tamsons to Head of Business Area Enterprise Wireless Solutions. Both Houghton and Tamsons will report to Borje Ekholm, President and CEO of Ericsson. These appointments underscore Ericsson's commitment to accelerating its business transformation. Chris Houghton, who is currently Senior Vice President, Market Area North East Asia, has been with Ericsson for 35 years and brings deep institutional knowledge across key markets and operational areas of the business. In the new role, Houghton will focus on cross group initiatives, including ongoing cost efficiency initiatives. The appointments of Chris Houghton and Asa Tamsons are effective as of November 1, 2023. As of then, Business Area Technologies & New Businesses, will report to the Chief Operating Officer.

13:30 EDT Delta Air Lines extends travel waiver on Tel Aviv flights - Delta has extended a travel waiver for all customers with travel booked to/from Tel Aviv and is notifying customers of refund options and cancellations. Delta also added that it is continuously monitoring the security environment in Israel to inform cancellations to its Tel Aviv flight schedule. The company has extended our waiver for all customers currently booked to/from Tel Aviv's Ben Gurion Airport so they can rebook their travel on available flights through Sept. 6, 2024. The waiver also allows these customers to process their own refunds via the Fly Delta app, delta.com or by calling Delta Reservations for refund support. Delta is canceling all its TLV flights through Oct. 31. While booking is suspended for TLV flights to/from Hartsfield-Jackson Atlanta International Airport and Boston Logan International Airport, customers can make reservations on flights between New York's John F. Kennedy International Airport and TLV for travel Nov. 1 and beyond. Seats on Delta partner airlines remain bookable on Delta.com and Delta Reservations when available.

13:23 EDT Brink's says not in talks with NCR about strategic transaction - Brink's Company (BCO) said it is not in discussions about a possible strategic transaction with NCR Corporation (NCR).

12:00 EDT Luxfer falls -15.4% - Luxfer is down -15.4%, or -$2.07 to $11.37.

12:00 EDT DaVita falls -19.5% - DaVita is down -19.5%, or -$17.82 to $73.47.

12:00 EDT Harmony Gold rises 6.7% - Harmony Gold is up 6.7%, or 28c to $4.54.

11:58 EDT Block says closed out HASI short position 'at some point' previously - Carson Block of short-selling firm Muddy Waters is being interviewed on CNBC.

11:32 EDT Huntington Ingalls awarded $347M U.S. Navy Lionfish contract - HII announced that its Mission Technologies division was awarded a contract to build nine small unmanned undersea vehicles for the U.S. Navy's Lionfish System program. The contract has the potential to grow to as many as 200 vehicles over the next five years with a total value of more than $347M. The Lionfish System, based on HII's REMUS 300, is a highly portable, two-person SUUV with an open architecture design and versatile payload options. In early 2022, REMUS 300 was chosen as the Navy's official program of record for the next-generation SUUV.

11:02 EDT Mercury Insurance announces continued partnership with Anaheim Ducks - Mercury Insurance announces its continued sponsorship of the Anaheim Ducks for the 2023-24 NHL season, honoring both the Ducks' 30th anniversary and Mercury's ninth successive year of collaboration with the team. This season, as part of Mercury's "My First Game" campaign, the company will work with the Anaheim Ducks Foundation whose mission is to facilitate and support programs that produce positive change for children and families throughout Southern California. The foundation will identify fans who have never attended a Ducks game and provide them with tickets, jerseys, dinner and screen time on camera to be introduced to the crowd.

10:55 EDT Sharecare jumps after Claritas forwards $1.35-$1.80 per share takeover bid - Sharecare's stock is up 19c, or 20%, to $1.13 in early Wednesday trading following a regulatory filing made earlier that revealed that on October 3, John Chadwick, a member of the board of directors of Sharecare, submitted a preliminary non-binding proposal to the board on behalf of Claritas Capital, related to the proposed acquisition, directly or indirectly, by Claritas and/or their affiliated investment funds of all of the shares of common stock not beneficially owned by the reporting persons for cash consideration of between $1.35 and $1.80 per share. "Each of Mr. Chadwick and the other the Reporting Persons reserve the right to modify or withdraw the Proposal at any time for any reason, including but not limited to an inability to secure financing for the Proposal on acceptable terms or at all and the satisfactory completion of due diligence, and no binding obligation on the part of any of Mr. Chadwick, Claritas Capital, the other Reporting Persons or any of their affiliates will arise with respect to submission of the Proposal or the filing of this Statement," the filing stated. The board has not yet responded to the proposal, the filing added. Reference Link

10:32 EDT Incyte: Data from Phase 3 TRuE-V demonstrates efficacy of Opzelura treatment - Incyte announced new results of a pooled analysis of long-term extension data from the pivotal Phase 3 TRuE-V program assessing Opzelura cream 1.5% in patients 12 years of age and older with nonsegmental vitiligo who previously experienced limited or no response to treatment at Week 24. These data were presented today in a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress 2023, held from October 11-14 in Berlin. "We are excited by the TRuE-V LTE study data presented today during a late-breaking session at EADV. These long-term data highlight encouraging updates for an important sub-group of patients with nonsegmental vitiligo, those who initially showed limited or no response to treatment," said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte. Key findings from the pooled analysis include: More than half of patients who initially experienced limited or no facial repigmentation at Week 24 achieved greater than or equal to75% improvement in facial repigmentation from baseline with continued treatment with Opzelura at Week 104. Half of the patients who initially experienced limited or no body repigmentation at Week 24 achieved greater than or equal to50% improvement in body repigmentation from baseline with continued treatment with Opzelura at Week 104. Among patients with no body repigmentation at Week 24, T-VASI improvements were observed in 79.6% and 93.3% of patients at Weeks 52 and 104, respectively. Among patients with limited body repigmentation at Week 24, T-VASI improvements were observed in 64.5% and 81.6% of patients at Weeks 52 and 104, respectively.

10:18 EDT MoonLake Immunotherapeutics presents 12-week data from Phase 2 MIRA trial - MoonLake Immunotherapeutics announced that 12-week results from its global Phase 2 MIRA trial evaluating the efficacy and safety of the Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa were presented today during a late-breaking session at the European Academy of Dermatology and Venereology Congress held in Berlin, Germany. The EADV presentation follows the announcement, in June 2023, of the topline 12-week results from the trial in 234 patients, which marked a landmark milestone as the first placebo-controlled randomized trial in HS to report results using HiSCR75 as the primary endpoint. The primary analysis was based on the most stringent type of analysis for such trials, intent-to-treat non-responder imputation. The MIRA trial met its primary endpoint with a significantly higher proportion of patients treated with both sonelokimab 120mg and 240mg achieving HiSCR75 compared to those on placebo at week 12. Sonelokimab also met the key secondary endpoint with a significantly higher proportion of patients treated with both sonelokimab 120mg and 240mg achieving HiSCR50 compared to those on placebo at week 12. Both doses performed similarly, with the 120mg dose providing the highest delta on HiSCR75 and HiSCR50. The 120mg dose achieved a 29 percentage points delta to placebo on HiSCR75 and a 38 ppt delta to placebo on HiSCR50. As early as week 8, a significant difference in response between sonelokimab and placebo was observed across HiSCR thresholds, including HiSCR90. In addition, other clinically relevant secondary endpoints also reached statistical significance at week 12 with sonelokimab compared with placebo. This included improvements in International Hidradenitis Suppurativa Severity Score System 4, significantly greater complete resolution of draining tunnels as well as significant improvements in patient reported quality of life, skin pain, and HS symptoms. The safety profile of sonelokimab was consistent with previously reported studies with no new safety signals observed. Overall, sonelokimab continues to show a favorable safety profile, in line with the known profile of IL-17 inhibitors. Full results from the MIRA trial will be submitted for publication in a peer-reviewed medical journal and for presentation at an upcoming scientific meeting.

10:00 EDT Fresenius Medical falls -16.8% - Fresenius Medical is down -16.8%, or -$3.53 to $17.42.

10:00 EDT Rayonier Advanced Materials rises 6.7% - Rayonier Advanced Materials is up 6.7%, or 22c to $3.49.

10:00 EDT MiX Telematics rises 8.8% - MiX Telematics is up 8.8%, or 50c to $6.16.

09:47 EDT Luxfer falls -14.4% - Luxfer is down -14.4%, or -$1.93 to $11.51.

09:47 EDT DaVita falls -16.3% - DaVita is down -16.3%, or -$14.87 to $76.41.

09:47 EDT AZZ Inc. rises 7.8% - AZZ Inc. is up 7.8%, or $3.60 to $49.50.

09:38 EDT Cosmos Health to acquire Cloudscreen for initial purchase price of $1M - Cosmos Health entered into a purchase agreement to acquire Cloudscreen, an AI powered platform. Cloudscreen is a multimodal platform for drug repositioning and repurposing. It integrates both 1D and 3D data types into its AI algorithm, which thoroughly analyzes the druggable proteome and variome, offering accurate predictions for repurposing of existing drugs toward new indications. The platform is accompanied by in vitro validation for both toxicity and effectiveness. The planned acquisition of Cloudscreen encompasses the software, its registered trademark, and associated know-how. The founders of Cloudscreen and its senior scientific team would continue to lead and manage the research, initiation, and execution of new drug repurposing projects. As a starting point, Cloudscreen's team is anticipated to undertake five repurposing projects, with the potential for each project to lead to patent filing upon successful completion of the in vitro validation phase. The total investment is expected to exceed $5M through 2029. This amount includes an initial purchase price of approximately $1M: EUR 300,000 in cash and a stock consideration valued at $700,000, based on an issuance price of $2.50 per share. Additionally, there will be an ongoing annual investment of EUR 400,000 for the initiation of repurposing projects, along with the recruitment of key scientific and technical personnel.

09:36 EDT Athena Consumer Acquisition Corp trading halted, volatility trading pause

09:33 EDT Better Therapeutics announces topline findings from AspyreRx analysis - Better Therapeutics announced top-line findings from a recent subgroup analysis of AspyreRx in its pivotal trial for type 2 diabetes, or T2D. The analysis reveals that adjunctive use of AspyreRx with standard of care, including GLP-1 receptor agonists, leads to a substantially greater clinical improvement compared to control participants who did not incorporate AspyreRx into their regimen. The subgroup analysis, involving approximately 160 participants on GLP-1s randomized to the active and control arm of the study, exhibited an average reduction in HbA1c of 0.7% at 90 days, between the two groups. This exceeds the results of the entire BT-001 pivotal trial population, where AspyreRx outperformed the standard of care control arm by 0.4%. Both reductions were statistically significant when compared to the corresponding control group. In addition to improvements in HbA1c at day 90, participants that were on both GLP-1 medications and AspyreRx also showed greater HbA1c reduction, greater weight loss, and utilized fewer medications at day 180 when compared to participants on GLP-1 medications without AspyreRx. The data for this subgroup analysis are being submitted for peer-reviewed publication. As previously reported, the BT-001 pivotal trial, the largest randomized controlled study ever conducted of a digital therapeutic to evaluate glycemic response in participants with T2D, met both its primary and secondary endpoints demonstrating statistically and clinically meaningful reductions in HbA1c over the control group receiving standard of care. The results achieved were sustainable and improved between day 90 and day 180 of the trial, demonstrating that AspyreRx has the potential to deliver meaningful, durable improvements in blood sugar control for a complex range of patients with T2D already on blood sugar lowering medications. In addition, exploratory data revealed a host of cardiometabolic improvements alongside reduced medication and healthcare utilization in comparison to the control group, supporting the potential for AspyreRx to improve the overall health of patients with T2D and potentially reduce increasingly costly interventions associated with the progression of the disease. A cost effectiveness analysis, which was part of a broader Health Economics and Outcomes Research conducted by Better Therapeutics, indicates that the utilization of AspyreRx may not only be more effective than standard of care alone but may also be less costly for payers. The new subgroup analysis data may be particularly relevant in the context of recent draft guidance from the FDA, titled 'Regulatory Considerations for Prescription Drug Use-Related Software,' released in September, which provides clarity about the agency's views and intent to consider the combined effectiveness of pharmaceuticals and digital therapeutic solutions when making drug labeling decisions.

09:28 EDT CVS Health says 'do not have knowledge of final 2024 Star ratings' - CVS Health issued the following statement on 2024 Star ratings: "At this time, CMS has not disclosed the final 2024 Star ratings. Accordingly, CVS Health and Aetna do not have knowledge of the final 2024 Star ratings and cannot confirm the ratings at this time."

09:26 EDT Renovaro BioSciences appoints Avram Miller to board of directors - Renovaro Biosciences announced that Avram Miller will join its Board of Directors. Beyond this board position, Mr. Miller will also take on an advisory role, contributing to the company's strategy and business development efforts. He co-founded Intel Capital and served as Intel's Corporate Vice President of Business Development.

09:20 EDT Terreno Realty acquires industrial property in California for $45.7M - Terreno Realty acquired an industrial property located in Redondo Beach, California for a purchase price of approximately $45.7M. The property consists of one industrial transshipment building containing approximately 67,000 square feet and one industrial flex building containing approximately 45,000 square feet on 6.7 acres. The property is at 2411 Santa Fe Avenue, west of Interstate 405 between Los Angeles International Airport and the ports of Los Angeles and Long Beach, provides 23 dock-high and one grade-level loading positions and parking for 200 cars. The property is 100% leased to two tenants and the estimated stabilized cap rate is 5.3%.

09:17 EDT C3 AI, Shell expand collaboration for asset monitoring, predictive maintenance - C3 AI announced that the C3 AI Reliability application will now include predictive maintenance software developed by Shell. Shell's predictive maintenance technology will continue to run on C3 AI Reliability as the two companies are close collaborators. ..Now, C3 AI will integrate this predictive maintenance technology into the C3 AI Reliability application, making it available to other customers and further advance C3 AI Reliability as the industry standard for predictive maintenance. To realize the most value from AI, C3 AI and Shell are pursuing a roadmap starting with reliability and asset monitoring solutions, focusing on safety, asset integrity, process and production optimization, and sustainability solutions. This collaboration marks a continued commitment of the C3 AI program across Shell. In addition, this collaboration will streamline the offerings available within the Open AI Energy Initiative marketplace. Founded in early 2021 by C3 AI, Shell, Baker Hughes, and Microsoft, the OAI Energy is an open ecosystem of AI-based solutions for the energy and process industries. Shell's OAI Energy offerings, including the Shell Predictive Maintenance for Control Valves application, will still be available on the OAI Energy platform for purchase by members.

09:10 EDT Sunworks awarded commercial grade EV charging system contract - Sunworks signed an agreement with an existing solar PV customer to install multiple commercial grade electric vehicle charging systems. This Sunworks agricultural customer is expanding its commitment to sustainability by adding an EV charging system to support the EV charging needs of its employees, customers, and to power electric farm equipment.

09:08 EDT GSK to present new data from B-Together phase IIb trial at AASLD meeting - GSK plc announced it will present 14 abstracts at the American Association for the Study of Liver Diseases' AASLD The Liver Meeting 2023, taking place in Boston, MA from November 10-14. Presentations feature data from two novel investigational specialty medicines, bepirovirsen, an antisense oligonucleotide for chronic hepatitis B, and linerixibat, an ileal bile acid transporter inhibitor for cholestatic pruritus in primary biliary cholangitis, or PBC. Key data include the first oral presentation of full results from the B-Together phase IIb trial investigating bepirovirsen followed by pegylated interferon alfa as treatment for people with CHB on nucleos(t)ide analogue therapy, the company noted. Chris Corsico, SVP, Development, GSK said: "We're looking forward to highlighting research in a variety of serious liver conditions, stemming from our expertise in infectious disease, immunology and human genetics. Our presentations include new data for bepirovirsen which not only further our understanding of its durability of response and role as a future backbone of chronic hepatitis B treatment, but also improve our understanding of the heterogeneous nature of hepatitis B infections. These data across chronic liver diseases demonstrate our enduring commitment to ultimately improve patient care."

09:07 EDT Interactive Strength to acquire CLMBR, transaction expected to close in Q4 - Interactive Strength, Inc. d/b/a FORME announced that it has entered into a definitive agreement to acquire substantially all of the assets of CLMBR, Inc., the maker of the first-to-market connected vertical climber. Trent Ward, Co-Founder and CEO of FORME, said: "We believe this will be a transformational acquisition that can accelerate the Company's commercialization path. Further, we believe the combination of these businesses can create tremendous value for all of our shareholders." Ward continues, "We expect this transaction can help us achieve immediate scale across all of our cost centers, resulting in a high-growth, profitable platform that sells connected fitness equipment and digital fitness services across B2B and B2C channels." FORME and CLMBR have executed a binding acquisition agreement and are proceeding towards closing the transaction as soon as all closing conditions are met by all parties involved, which is expected to be in the fourth quarter of 2023. Transaction Highlights: The pending acquisition is expected to yield several strategic and financial benefits, positioning the combined entity for further growth: Rationale: Expected to provide immediate scale in all functions; Generates material and near-term cashflow for TRNR; Diversifies revenue, with significant growth in B2B channel; Gaining strong B2B distribution partner in WOODWAY. Projected financials: Combined revenue in 2024 is expected to exceed $20 million; Run-rate cashflow positive and adjusted EBITDA profitable potentially as early as the fourth quarter of 2024. Valuation: Enterprise Value of deal is $16.9 million; Approximately 1x EV / Projected 2024 CLMBR revenue; Between 2x and 4x EV / Projected 2024 CLMBR EBITDA, pro-forma for synergies. Consideration: $6.0 million of TRNR common equity issued at transaction close; Number of shares is determined by the VWAP for the ten days before the close of transaction, with min/max of $1.01 and $1.69 per share; Earn-out potential for achieving certain levels of B2B unit sales in 2024, paid in TRNR common equity; $1.5 million of subordinated debt assumed; $9.4 million senior debt to be refinanced. Timing: Expected to close as early in the fourth quarter of 2023

09:05 EDT AvePoint announces launch of AI Trust Foundation - AvePoint hosted the launch of the AI Trust Foundation, a non-profit membership organization designed to be the leading voice for promoting beneficial AI through education and outreach at all levels of society, at its #shifthappens Conference in Washington, D.C. Founding members of the AI Trust include Pryor Strategy Group and AvePoint. Partners supporting the AI Trust include 501cStrategies, Global Impact and Pillsbury.

09:03 EDT Fortinet announces eight new MSSPs adopt Fortinet Secure SD-WAN - Fortinet announced that eight new managed security service providers have recently added Fortinet Secure SD-WAN to their portfolios to deliver new value-added managed services for their customers. Automation Sensei, CommandLink, Converge ICT Solutions Inc., Evolutio, HCLTech, Proximus, Tigo Business, and TM One join a growing list of global service providers utilizing Fortinet Secure SD-WAN as the foundation for new and differentiated secure networking services.

09:02 EDT Sintx awarded Phase II NIH grant for Silicon Nitride-PEEK 3D implants - SINTX Technologies announced it has been awarded a Phase II grant of $1,972,826 by the National Institutes of Health, NIH, to develop a 3D printed composite silicon nitride - polyetheretherketone, SN-PEEK, spinal implant. This represents the fourth NIH grant awarded to SINTX since the Phase I award for this project was received in September of 2021. SINTX will collaborate with the University of Pennsylvania School of Veterinary Medicine over the next 24 months to execute this project. The NIH grant will support resourcing and acquisition of materials as well as testing and trials at SINTX and Penn Vet. Upon the successful execution of the Phase II grant application goals, SINTX will have the majority of the benchtop and large animal in vivo data needed to seek FDA regulatory clearance using the 510(k) pathway. Additionally, successful demonstration of infection prevention in vivo will be a critical step towards enabling an antimicrobial device claim. "In the Phase I effort, Dr. Steven Kurtz of Drexel University and Dr. Noreen Hickok of Thomas Jefferson University were the lead university investigators while Dr. Thomas Schaer of Penn Vet provided valued consultative support for study and implant design. These scientists provided significant contributions to the proposal, and we are grateful for their continued support," said Dr. Sonny Bal, President, and CEO. "Dr. Schaer will be the lead investigator at Penn Vet while Drs. Kurtz and Hickok will assume advisory roles on the project during execution of Phase II activities. Since the NIH grant will fund the acquisition of needed benchtop data and the first ever in vivo performance data for SN-PEEK devices, the award represents a critical milestone in expanding the antibacterial and osseointegrative properties of silicon nitride into composite structures.."

09:01 EDT Edgewell Personal Care names LaTanya Langley as Chief People and Legal Officer - Edgewell Personal Care announced changes to its executive team to streamline leadership structure and support the company's strategic objectives. With the planned departure of John Hill, Chief Human Resources Officer, a new role of Chief People and Legal Officer has been created. LaTanya Langley, Chief Legal Officer, will be appointed to the new role effective November 6, 2023. Langley joined Edgewell in 2022 to lead Edgewell's legal matters including overseeing the company's litigation and disputes, intellectual property, contracting, compliance program, and providing legal counsel relating to all regulatory, sales and marketing. Hill will remain at Edgewell to transition his responsibilities to Langley through the end of calendar 2023.

08:56 EDT Tempest Therapeutics sees needing 'north of $100M' to develop drug on its own - On the TPST-1120 Global Randomized Phase 1b/2 Combination Study Data Call, Tempest Therapeutics that that if Tempest were to "do this 100% alone," it would need "north of $100M" to do the study, but notes that "this drops dramatically" in a partnership. In a partnership, Tempest says the company would need to raise "under $50M" to be able to do the full phase 3 study.

08:52 EDT Revive Therapeutics provides update on novel bucillamine formulation development - Revive Therapeutics provides an update on the development of a next generation lyophilized formulation of Bucillamine. Under an agreement with the University of Waterloo, formulation development is ongoing and aims to be completed by the end of December 2023. Discussions with contract development manufacturing organizations with expertise in the clinical manufacturing of lyophilized products are ongoing. The Company expects to have its novel lyophilized formulation of Bucillamine ready for clinical evaluation in 2024. The Company intends to explore the novel Bucillamine formulation as a potential treatment for public health medical emergencies including, pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. In addition, as a potent antioxidant and anti-inflammatory, Bucillamine may be useful for orphan indications in rare inflammatory disorders such as ischemia-reperfusion injury resulting from solid organ transplantation.

08:48 EDT CNS Pharmaceuticals enrolls 229 of expected 243 patients in berubicin study - CNS Pharmaceuticals has achieved enrollment of 229 of the expected 243 patients in the ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer. The Company has opened 46 clinical trial sites across the U.S., Italy, France, Spain, and Switzerland. As previously announced, CNS Pharmaceuticals has reached the criteria required by the study protocol to conduct a pre-planned, non-binding futility analysis, which an independent Data Safety Monitoring Board will review to determine whether to recommend continuing the study as planned or modifying the study based on Berubicin showing potential value as a second-line treatment for patients with glioblastoma. CNS Pharmaceuticals previously reported that the Company would conduct this analysis after at least 50% of the patients in the population to be analyzed for the interim analysis had reached the primary efficacy endpoint, as provided for in the study protocol. The DSMB will review the number of deaths in each arm to ensure that the overall survival of patients receiving Berubicin shows at least a statistically significant comparability to those receiving Lomustine. Additional analyses will include comparisons of secondary endpoints, including progression-free survival response rates, and safety assessments. Upcoming Expected Milestones: Report topline results of interim analysis expected in Q4 2023. Enrollment will continue during the interim analysis.Complete enrollment in Q4 2023.

08:42 EDT Ondas apppoints Timothy Tenne as CEO of American Robotics - Ondas Holdings announced that Timothy Tenne has been appointed as CEO of American Robotics. Tenne will be responsible for driving platform adoption of the Optimus and Iron Drone Systems and building the field operations capability to support the delivery and scaling of aerial data solutions for government and industrial customers across the Americas. Under Mr. Tenne's leadership, American Robotics will continue to support the ongoing operations in Israel and the Middle East together with the executive team across Ondas and Airobotics. He joins Ondas from Nordic Unmanned, where he was CEO of North America operations and helped open the U.S. market for Nordic Unmanned's technology and services.

08:41 EDT American Resources' ReElement files to convert from LLC to corporation - American Resources Corporation's ReElement Technologies has filed the necessary paperwork to convert from a LLC to a corporation in preparation of its spinoff into a standalone public company under the name ReElement Technologies Corporation with a reserved ticker of RLMT. Conversion of the company to a corporation will allow for the common shares of ReElement to be distributed proportionally to the shareholders of American Resources Corporation, at a record date that will be set by the Board of Directors and communicated to shareholders. The Company, its Board of Directors and Special Committee have set out the following objectives which are in process: Spinoff ReElement into an independently run and operated business focused on the pure play refining of battery and rare earth elements into battery and magnet grade; Monetization of the metallurgical carbon mining business either through the sale or spinoff of such assets; and Focus on American Resources, post such events, taking ownership stakes in attractive critical mineral and rare-earth element resources opportunities.

08:38 EDT Paltalk appoints Cook to board of directors - Paltalk announced that Geoffrey Cook was appointed to the board of directors of the Company, effective immediately. The Company increased the size of the board of directors from five directors to six directors, and Cook was selected to fill the newly created vacancy. Jason Katz, Chairman and CEO of Paltalk, commented, "We are thrilled to have Geoff join our board of directors at this time, as we embark on further advancing our business both organically and acquisitively. His experience, knowledge, and success in growing The Meet Group, and ultimately selling it in 2020 for $500 million to ProSiebenSat.1 Media, enables Geoff to provide us valuable guidance going forward. We look forward to Geoff's insight and input as we evaluate the Company's opportunities and continue to build and execute strategic plans."

08:38 EDT Emerson Electric completes acquisition of National Instruments - Emerson (EMR) announced it has closed its acquisition of NI (NATI), a provider of software-connected automated test and measurement systems, at an equity value of $8.2B. NI will become a new reported segment within Emerson called Test & Measurement and will be consolidated into the Software and Control group. As a result of the transaction's closing, NI's common stock has ceased trading on the Nasdaq.

08:38 EDT Quisitive Technology collaborates with Microsoft for healthcare data solutions - Quisitive Technology will collaborate with Microsoft to leverage the new healthcare data solutions in Microsoft Fabric for Ontario Workers Network, the Ottawa Hospital, and other hospitals in the network. Fabric is an end-to-end, unified analytics platform that seamlessly integrates various data and analytics tools like Microsoft Azure Data Factory, Azure Synapse Analytics, and Power BI into a single unified product, empowering healthcare professionals to unlock the potential of their data to better serve patient needs. Quisitive is leveraging Microsoft solutions for OWN to securely migrate 35,000 patient files from a legacy database to Fabric, producing new insights about patient health. The migration will increase efficiency and capacity in data analysis for healthcare organizations by utilizing the rich capabilities of Fabric.

08:37 EDT Bridgeline Digital signs $6M in new customer contracts in fiscal 2023 - Bridgeline Digital provided the following update for the end of its fiscal year 2023. In fiscal 2023, Bridgeline signed more than $6M in new license contracts and had a revenue renewal rate of more than 90%. The HawkSearch product line led the company's success with HawkSearch growing to nearly 50% of Bridgeline's revenue with a revenue renewal rate of more than 95%. In its fourth quarter, Bridgeline booked an additional 27 sales for $900 thousand in contract value that adds $375 thousand in annual recurring revenue. Bridgeline closed the fourth quarter with a 92% revenue renewal rate for $2 million in contracts, totaling $9 million in renewals for the year. "By powering product discovery, our platform enables businesses to grow revenue. Not only do we drive more visitors to websites, but we also ensure those visitors become customers and make larger purchases," commented Ari Kahn, Bridgeline's CEO. "Our consistent track record of boosting online visits by up to 25%, elevating conversions by 35%, and raising the average transaction value by 25% attracts many to our software."

08:35 EDT Yield10 provides update on recent advancement in development of Camelina - Yield10 Bioscience announced recent advancements toward enabling weed control for Camelina cultivation and supporting grower adoption of the crop for production of low-carbon intensity feedstock oil for the biofuel market. Control of broadleaf weeds is essential for the rapid adoption and success of commercial crops in North America. Yield10 is establishing a leadership position in the development of herbicide tolerant Camelina to drive broad acceptance of the crop by growers. The Company is developing Camelina with tolerance to a broad leaf herbicide, which has been used safely in commercial crop production for over 25 years. In addition, Yield10 is developing an herbicide package for Camelina, incorporating tolerance to over-the-top application of broadleaf herbicide as well as tolerance to soil residual Group 2 herbicides, which are commonly used to control weeds in cereal crops. "The Yield10 team is making significant progress toward our goal of launching elite herbicide tolerant Camelina for producing feedstock oil for the biofuels market," said Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience. "We aim to facilitate the seamless integration of Camelina with current weed control and crop rotation practices of major crops in order to enable the planting of Camelina on large-scale acreage. This winter, we anticipate that our program will achieve another important milestone as we conduct field tests of stacked HT winter Camelina for the first time. We will also continue to execute on seed scale-up and regulatory activities in support of the planned commercial launch of our elite HT and stacked HT Camelina varieties."

08:35 EDT Relmada Therapeutics reports preclinical data on its novel psilocybin - Relmada Therapeutics announced that new preclinical data on its novel psilocybin will be highlighted in a poster presentation at the American Association for the Study of Liver Diseases, or AASLD, The Liver Meeting 2023, being held November 10-14, 2023, in Boston, MA. The data demonstrate the beneficial effect of non-psychedelic/low dose psilocybin on multiple metabolic parameters in a rodent model of metabolic dysfunction-associated steatotic liver disease, or MASLD. Mice were fed a high fructose, high fat diet, or HFHFD, for 17 weeks to induce MASLD, along with hyperglycemia, hyperlipidemia and significant weight gain. One group of MASLD mice was treated with low-dose psilocybin daily and a second with vehicle daily by oral gavage while continuing on HFHFD. Standard diet-fed mice were used as controls. Body-weight and food intake were assessed weekly. Key statistically significant results in psilocybin-treated mice relative to HFHFD vehicle-treated mice include: Significantly reduced hepatic steatosis; 12% reduction in body weight gain with no reduction in food intake; Significant decrease in fasting blood glucose level and AUC in an Oral Glucose Tolerance Test

08:33 EDT Sellas Life announces first patient dosed in Phase Ib/II trial of SLS009 - SELLAS Life Sciences announced that its partner GenFleet Therapeutics has dosed the first patient in a Phase Ib/II trial evaluating SLS009 in relapsed/refractory Peripheral T-cell Lymphomas, PTCL. The open-label, single-arm trial will enroll up to 95 patients to evaluate safety and efficacy and, based on the results, may serve as a registrational study. This initial PTCL study is fully funded by GenFleet and is being conducted in China. "SLS009 is a novel and highly selective CDK9 inhibitor which, to date, has shown tremendous therapeutic promise across multiple blood cancers," said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. "We are pleased with the initiation of the Phase Ib/II trial of SLS009 in the underserved PTCL patient population. Collaborating with GenFleet amplifies the potential of our highly selective CDK9 inhibitor in multiple indications and reflects our joint commitment to delivering this groundbreaking treatment to cancer patients globally. While our primary efforts are focused on acute myeloid leukemia in the United States, we remain fully supportive and deeply involved in the PTCL study and will make further development decisions for this indication as we obtain initial data for this Phase Ib/II study from our partner."

08:32 EDT AbbVie announces new data from Phase 3 studies of RINVOQ - AbbVie announced new data analyses from the Measure Up 1, Measure Up 2 and AD Up Phase 3 studies that further demonstrated the long-term efficacy and safety profile of RINVOQ, or upadacitinib, among adults and adolescents 12 years and older with moderate to severe atopic dermatitis through 140 weeks. Study results will be orally presented on Wednesday, October 11, at the 32nd European Academy of Dermatology and Venereology, or EADV, Congress in Berlin. In the Measure Up 1, Measure Up 2 and AD Up Phase 3 studies, a significantly higher proportion of patients treated with upadacitinib achieved the co-primary endpoints of improvement in skin clearance, measured by an EASI score of 75 and vIGA-AD 0/1 at week 16, compared to those who received placebo.1 Additionally, more upadacitinib-treated patients achieved the secondary endpoint of improvement in skin clearance, measured by an EASI score of 90, and an additional endpoint of itch reduction at week 16, compared to placebo-treated patients.1 The efficacy of both upadacitinib doses was consistently maintained for these important measures across all three studies through week 140.1

08:32 EDT Ally Financial CEO Jeffrey Brown to step down early next year - Ally Financial announced that Jeffrey Brown will be stepping down early next year after serving as CEO and a member of Ally's Board of Directors since 2015. The Board has engaged a leading global executive search firm, and the search for a successor is underway. Brown will remain with Ally until January 31, 2024, or an earlier date determined by the Chair of the Board to help ensure a smooth leadership transition. Following his departure, Brown will become President of Hendrick Automotive Group, a longtime customer of Ally and the largest privately held automotive retail organization in the United States with nearly 11,000 employees and 131 retail franchises across 13 states.

08:21 EDT CISO Global listed on PCI Marketplace as Qualified Security Assessor - CISO Global has been added to the PCI Marketplace as a PCI Quality Security Assessor, QSA. In this role, CISO Global is certified and authorized by the Payment Card Industry Security Standards Council, PCI SSC, to assess and validate the compliance of organizations with Payment Card Industry Data Security Standard, PCI DSS. As a PCI QSA, CISO Global performs security assessments to verify PCI DSS compliance. During these assessments, CISO Global determines whether merchants have met information security requirements specified in the PCI DSS. In addition, CISO Global is working with clients to help them achieve the new PCI DSS 4.0 Compliance standard that accounts for technological and process advancements over the past 13 years. "We are committed to helping the industry meet the increasing list of regulatory requirements as seamlessly as possible," added CISO Global CEO David Jemmett. "Our teams are focused on meeting these soon-to-be critical requirements for increased standards and practices to secure credit card data and better protect merchants and their customers so they can continue to operate their businesses without interruption."

08:20 EDT Thoughtworks modernizes financial operations with Stripe - Thoughtworks announced joining Stripe's Partner Ecosystem to provide solutions that enable modern digital commerce and financial operations to enterprises of all sizes. In today's digital era, organizations must accelerate entry into new markets while delivering better customer service, cutting costs and growing revenue. Businesses are limited by large complex legacy infrastructures, manual processes and specialized skill sets - even culture. With Thoughtworks' Financial Operations Modernization framework, powered by Stripe, operational finance leaders can implement seamless customer experiences, improve speed and accuracy of financial processes, gain better visibility into their financial health and make better decisions"We started on our transformation journey because we knew it was the future and we wanted to modernize and help tradespeople better streamline and grow their business while continuing to delight their customers," said Jeremy Burton, Chief Technology Officer of hipages Group, home of Australia's #1 online tradie marketplace.. "Thoughtworks' financial modernization solution powered by Stripe, has made the payments experience even simpler and smoother for our trusted tradespeople and their customers." ...

08:18 EDT Bionano Genomics implements streamlined operational plan - On October 9, 2023, Bionano committed to a series of cost savings initiatives including a reduction in force and reducing facility costs and discretionary spending unrelated to headcount that, taken together with cost savings realized from the reduction in force the Company announced in May, is expected to result in a reduction of non-GAAP operating expenses by approximately $31.6 million on an annualized basis starting in 2024, excluding savings in stock-based compensation. Part of the savings comes from a reduction in force of 66 positions eliminated as part of the October 2023 initiatives, which, when combined with the positions eliminated since May 2023, is expected to bring the number of employees planned for December 31, 2023 to 321. Cost of goods sold is expected to be reduced by approximately $1.4 million on an annual basis, starting in 2024, in connection with the October 2023 initiatives, which will be a component of anticipated improvements to gross margin going forward.

08:15 EDT Yoshitsu to open direct-sale stores in the U.S. - Yoshitsu announced that the company plans to open direct-sale stores in the U.S. The Stores will be launched in five cities, including New York, Boston, Seattle, Las Vegas, and Los Angeles. Yoshitsu expects the opening of the Stores to bring about increased sales, and aspires to elevate the overall customer experience, and strengthen customer loyalty. Mei Kanayama, the Principal Executive Officer of Yoshitsu, commented, "Launching our direct-sale Stores in the U.S. is a transformative step for Yoshitsu. By streamlining operations in-house in the U.S., we're not just aiming to build closer ties with the U.S. market, but we are also seeking to enhance operational control to improve our service standards. We believe that the opening of the Stores will be instrumental in elevating our customers' shopping experience, from their initial interaction to post-purchase support. With this approach, we anticipate being able to introduce premium products and services that truly resonate with our patrons in the U.S."

08:13 EDT McEwen Copper announces additional $10M investment by Nuton - McEwen Copper, a subsidiary of McEwen Mining (MUX), announces a binding agreement for an additional $10.0M investment by Nuton, a Rio Tinto (RIO) Venture, and existing McEwen Copper shareholder. Nuton has agreed to invest US$10.0M to acquire shares of McEwen Copper in a two-part transaction expected to close by October 19th, 2023 consisting of a private placement of 152,615 McEwen Copper common shares, and the purchase of 232,000 common shares owned by McEwen Mining in a secondary sale. Proceeds of the subscription and purchase are expected to be approximately $4.0 million to McEwen Copper and $6.0 million to McEwen Mining, respectively. The proceeds of the private placement will be used to advance the development of the Los Azules copper project in San Juan, Argentina, and for general corporate purposes. After closing, Nuton will own 14.5% of McEwen Copper on a fully diluted basis, and McEwen Mining will own 47.7%. The transaction values McEwen Copper at approximately US$800 million.

08:11 EDT McEwen Copper closes ARS $42B investment by Stellantis - McEwen Copper, a subsidiary of McEwen Mining (MUX), announces the closing of an additional ARS $42B investment by Stellantis (STLA). Stellantis, which in February 2023 invested ARS $30 billion, has invested an additional ARS $42 billion in Argentina to acquire shares of McEwen Copper in a private placement of 1,900,000 common shares. The proceeds of the private placement will be used to advance development of the Los Azules copper project in San Juan, Argentina, and for general corporate purposes. Giving effect to the pending investment by Nuton LLC, also announced today, Stellantis increases its ownership to 19.4% of McEwen Copper and McEwen Mining owns 47.7% on a fully diluted basis. The Transaction values McEwen Copper at approximately US$800 million.

08:09 EDT authID selected by Workforce360 for automated candidate onboarding - authID and Workforce360 announced that they recently signed an agreement to leverage authID's identity verification services to automate identity document collection and streamline the delivery of trusted candidates to their network of recruitment agents and enterprise customers. authID was selected by Workforce360 because of its ability to deliver a fully orchestrated identity document capture and authentication solution that is fast, accurate, user-friendly, and globally focused. "authID is committed to delivering the best identity document verification solution in the market that eliminates identity fraud, while delivering the fastest and easiest user experience," said Rhon Daguro CEO of authID.ai. "We are excited to help Workforce360 deliver the highest levels of speed, transparency and identity trust in international workforce recruitment."

08:05 EDT Xwell unveils new corporate identity, enhanced website for Xpres Spa - XWELL announced a new brand identity and website redesign for its airport spa brand XpresSpa, which will now be visually represented as Xpres Spa Coinciding with Xpres Spa's 20th anniversary, the new website launch and logo aligns with management's ongoing focus to improve the user experience and drive sales growth in its flagship airport business. The Xpres Spa rebrand reflects the Company's continued effort to bring restorative, regenerative and reinvigorating products and services to travelers, strengthening its market position with a modern aesthetic and intuitive website. From a design and brand equity perspective, the new airport spa logo features a combination of the shape of ancient sundials and the warm, restorative powers of the sun.

08:04 EDT Precision Optical Technologies announces strategic partnership with Charter - Precision Optical Technologies announces its multi-year strategic partnership with Charter Communications. This partnership supports a pivotal moment in Charter's evolution of next-generation broadband services. In alignment with Charter's Distributed Access Architecture, or DAA, network expansion and operational enhancement initiatives, this collaboration will see the deployment of nearly all of Precision OT's active and passive portfolio of solutions; to include 10G DWDM tunable optics, 100G and 400G optics, Bluetooth DWDM tuning modules, passive connectivity solutions and more.

08:03 EDT Harmony Biosciences completes acquisition of Zynerba - Harmony Biosciences (HRMY) announced that it has completed its acquisition of Zynerba Pharmaceuticals (ZYNE). As a result of the merger, Zynerba became a wholly owned subsidiary of Harmony. The common stock of Zynerba will no longer be listed for trading on the Nasdaq Capital Market.

08:02 EDT PDS Biotechnology announces interim safety, immune response data on PDS0301 - PDS Biotechnology announced interim safety and immune response data for the first-in-human Phase 1/2 clinical trial evaluating PDS0301, a novel investigational tumor-targeting, antibody-conjugated Interleukin 12, in combination with current standard-of-care chemotherapy, docetaxel, to treat metastatic castration sensitive and castration resistant prostate cancer. The data will be featured in an oral presentation by Ravi Madan, MD, Head, Prostate Cancer Clinical Research Section, Genitourinary Malignancies Branch, Center for Cancer Research of the National Cancer Institute, an Institute of the National Institutes of Health, at the 11th Annual Meeting of the International Cytokine & Interferon Society in Athens, Greece. Eighteen patients with a median age of 69 years were evaluated for clinical activity and toxicity. Three dose levels of PDS0301 in combination with docetaxel were administered every three weeks beginning with the second cycle of treatment. The dose-limiting toxicity window spanned the 6 weeks after initiating docetaxel. While all doses of PDS0301 were well-tolerated, the 12.0 mcg/kg dose of PDS0301 with chemotherapy provided the best combination of immune response and tolerability. Interim data highlights to be presented at Cytokines 2023 include: Decrease in PSA levels was seen in all patients at all three tested doses of PDS0301 and ranged from -4% to -100%; All doses of the combination were well-tolerated with one patient experiencing Grade 4 neutropenia; Administration of the combination was associated with decreases in T reg cells and increases in activated natural killer cells, memory CD8 T cells, proliferating CD4 and CD8 T cells and cytokines INF-gamma and Interleukin 10; The changes in immune responses with the combination were independent of the PDS0301 dose

07:48 EDT Nutriband completes market assessment for AVERSA Buprenorphine - Nutriband has completed the market assessment and commercialization strategy for AVERSA Buprenorphine, an abuse deterrent buprenorphine transdermal system. The company engaged leading healthcare consulting company Health Advances to assess the market opportunity and commercial strategy for Aversa Buprenorphine, which has the potential to be the world's first buprenorphine transdermal system with abuse deterrent properties. Once approved by the United States FDA, Aversa Buprenorphine will be priced competitively with non-abuse deterrent options and may reach peak annual US sales of $70-130 million. The company is also considering developing the product for strategic international markets as protected by its global abuse deterrent patent portfolio.

07:44 EDT Piedmont Lithium enters agreements to acquire Killick Lithium interest - Benton Resources and Sokoman Minerals announced the entering into of the Definitive Agreements with Piedmont Lithium and its subsidiaries, enabling Piedmont to earn up to a 70% direct and indirect ownership interest in the area and lands comprising the Golden Hope project to be renamed the Killick Lithium Project, located in southwestern Newfoundland. Pursuant to the terms of the Transaction, each of Benton and Sokoman assigned all of its rights and interests to the Golden Hope Project to Vinland, a newly incorporated British Columbia corporation, in exchange for all of the issued and outstanding shares in the capital of Vinland, held by each in equal proportions, and, in turn, Vinland assigned the Golden Hope Project Rights to its newly incorporated, wholly-owned subsidiary, Killick. Upon the completion of the Reorganization, Vinland and Piedmont, entered into a subscription agreement pursuant to which Piedmont subscribed for a 19.9% ownership interest in Vinland for an aggregate subscription amount of CAD$2.0M; and a shareholders' agreement with Benton and Sokoman setting forth the framework for the governance of Vinland and for the holding, disposal and subsequent issuances of interests in Vinland. Upon the completion of the Subscription, Killick and Piedmont entered into an earn-in agreement, pursuant to which Piedmont was granted the option to acquire up to a direct 62.5% ownership interest in the Golden Hope Project, a royalty agreement pursuant to which Benton and Sokoman were granted an aggregate 2% royalty on the net returns of precious metals and the value of lithium received from the Golden Hope Project, and a marketing agreement pursuant to which Piedmont was granted the exclusive marketing rights for the promotion and sale of lithium products produced from the Golden Hope Project, including the right to purchase any uncommitted project production on commercially reasonable arm's length terms, the whole as further set forth below. Upon the acquisition of the Initial Interest, Vinland, Killick, and Piedmont shall enter into a shareholders' agreement pursuant to which the parties thereto set forth the framework for the governance of Killick and for the holding, disposal, and subsequent issuances of interests in Killick. Pursuant to the Earn-In Agreement, Piedmont was granted the option, exercisable by notice, to acquire a 16.35% voting and participating interest in Killick in consideration of the issuance by Piedmont to each of Benton and Sokoman of shares of its common stock having an aggregate subscription price of CAD$2.0M based on Piedmont's ten-day volume weighted average price up to the date of the Initial Interest exercise notice, and payment of work expenditures in the aggregate amount of at least CAD$6.0M within the 30-month period following the Initial Earn-In Right exercise notice.Upon exercise of the Initial Earn-In Right by Piedmont, Piedmont's combined direct and indirect ownership interest in Killick will be equal to approximately 33%. Within 60 days following the funding of the Initial Earn-In Amount, Piedmont shall have the option, exercisable by notice, to acquire an additional 21.65% voting and participating interest in Killick in consideration of the issuance by Piedmont to each of Sokoman and Benton of shares of its common stock having an aggregate subscription price of CAD$2.0M based on Piedmont's ten-day VWAP up to the date of the First Additional Earn-In Right exercise notice, and payment of work expenditures in the aggregate amount of at least CAD$3.0M within the 12-month period following the First Additional Earn-In Right exercise notice. Upon exercise of the First Additional Earn-In Right by Piedmont, Piedmont's combined direct and indirect ownership interest in Killick will be equal to approximately 50%. Within 60 days following the funding of the First Additional Earn-In Amount, Piedmont shall have the option, exercisable by notice, to acquire an additional 24.5% voting and participating interest in Killick in consideration of the issuance by Piedmont to each of Benton and Sokoman of shares of its common stock having an aggregate subscription price of CAD$6.0M based on Piedmont's ten-day VWAP up to the date of the Second Additional Earn-In Right exercise notice, and payment of work expenditures in the aggregate amount of at least CAD$3.0M within the 12-month period following the Second Additional Earn-In Right exercise notice. Upon exercise of the Second Additional Earn-In Right by Piedmont, Piedmont's combined direct and indirect ownership interest in Killick will be equal to approximately 70%. Concurrently with the entering into the Earn-In Agreement, Killick shall grant an aggregate 2% royalty on the net returns of precious metals and the value of lithium received from the Golden Hope Project to Benton and Sokoman; provided, however, that Killick, Piedmont or any of their successors shall have the right to repurchase 50% of such royalty in consideration for an aggregate cash payment of CAD$2.0M to Benton and Sokoman. As part of the Transaction, Killick and Piedmont entered into a marketing rights agreement granting Piedmont 100% marketing rights and the right to purchase, under a right of first offer, any uncommitted lithium concentrate produced by the Golden Hope Project on commercially reasonable arm's length terms.

07:38 EDT Piedmont buys 19.9% equity stake in newly-formed Vinland Lithium for C$2M cash - Piedmont Lithium announced a strategic investment in a large prospective lithium project in Newfoundland, Canada. Piedmont has agreed to pay C$2M for a 19.9% equity interest in Vinland Lithium a new entity established with Sokoman Minerals and Benton Resources . The Company also may earn up to a 62.5% equity interest in Killick Lithium a wholly-owned subsidiary of Vinland Lithium holding a 100% interest in the Killick Lithium Project through a staged investment agreement. Piedmont will be entitled to 100% marketing rights and a right of first refusal on 100% offtake rights to any lithium concentrate produced by the Project on a life-of-mine basis at competitive commercial rates. Killick Lithium Project relative to Piedmont Lithium's asset portfolioGeologically, the Killick Lithium property is analogous to the Carolina Tin-Spodumene Belt, which hosts Piedmont's Carolina Lithium project. The property totals 950 square kilometers and hosts approximately 60 kilometers of prospective strike length. Initial prospecting on the property by Benton Resources and Sokoman Minerals in 2021 led to the discovery of the first occurrence of spodumene-bearing pegmatite in Newfoundland.

07:36 EDT NCL Corporation announces proposed offering of senior secured notes - NCL Corporation is proposing to sell $790.0 million aggregate principal amount of its senior secured notes due 2029 in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended. The Notes and the related guarantees will be secured by first-priority interests in, among other things and subject to certain agreed security principles, fourteen of our vessels that will also secure our senior secured credit facility and our 8.375% senior secured notes due 2028. The Notes will be guaranteed by our subsidiaries that own the vessels that will secure the Notes. We intend to use the net proceeds from the Notes Offering, together with cash on hand, to repay the term loans outstanding under our senior secured credit facility, including to pay any accrued and unpaid interest thereon, as well as related premiums, fees and expenses. The completion of the Notes Offering is conditioned on certain amendments to our senior secured credit facility.

07:35 EDT Bombardier joins DOD SkillBridge program - Bombardier has joined the United States Department of Defense SkillBridge program as an authorized industry partner. The SkillBridge program helps U.S. service members bridge the gap between active duty and the beginning of their civilian careers with industry-specific training, apprenticeships, or internships offered by trusted employers. Bombardier was granted an official Memorandum of Understanding by the Office of the Deputy Assistant Secretary of Defense to develop SkillBridge training programs for applicable branches of the U.S. military.

07:34 EDT FTI Consulting launches FTI Delta practice - FTI Consulting announced the launch of FTI Delta, a global, industry-specialized strategy consulting practice that delivers tangible value to clients, from strategy definition to execution. FTI Delta will compete directly with traditional strategy consulting firms leveraging its differentiated value proposition. FTI Delta focuses on key industries where the firm has deep vertical expertise: telecommunications, media and technology and public sector. The FTI Delta team consists of more than 350 billable professionals, including 39 Senior Managing Directors, based in the United States, the United Arab Emirates, Spain, Singapore, South Africa, the United Kingdom, Canada, India and Saudi Arabia. The FTI Delta team combines the expertise of Delta Partners, an established strategy consulting business that FTI Consulting acquired in July 2020, with the extensive experience of industry experts within FTI Consulting's renowned TMT practice and the Company's newly formed Public Sector offering. The Public Sector offering works with governments to define their national visions and agendas, shape their future-ready economic and social development plans, and drive impactful transformations in public administration. FTI Delta sits within the Business Transformation & Strategy practice in the Corporate Finance & Restructuring business segment. Senior Managing Directors Luke Schaeffer and Victor Font will co-lead FTI Delta globally and will continue to lead the TMT practice.

07:32 EDT Vivos Therapeutics to begin clinical trial at Standford Medicine on DNA - Vivos Therapeutics announced that its flagship daytime-nighttime appliance, DNA, will be tested in a clinical trial at Stanford Medicine. The protocol has been finalized and participant enrollment will begin in early 2024. Study participants with moderate to severe OSA will be randomly assigned to either treatment with Vivos' DNA appliance or CPAP, the current industry standard for OSA treatment. Sleep studies will be performed prior to and following a course of treatment using in-lab polysomnography to assess changes in the patients' apnea-hypopnea index. "We are extremely excited to be starting this trial at Stanford Medicine, which has been in the works for some time" added R. Kirk Huntsman, Chairman and CEO of Vivos. "I am confident that our technology will bear the scrutiny of a well-designed, prospective clinical trial. There is no better place to for our technology to undergo rigorous scientific testing than at a respected institution like Stanford. Our treatment is comfortable, safe and non-invasive, and we believe that at the end of this study, the conclusion will be that Vivos should become an essential part of every OSA care plan."

07:31 EDT Phio Pharmaceuticals presents new data of its INTASYL compound PH-894 - Phio Pharmaceuticals announced the poster presentation of two key preclinical studies of its INTASYL compound PH-894 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts on October 11th -15th. The first study shows that melanoma cells treated with its PH-894 compound makes them more recognizable to the immune cells. Specifically, the treatment results in an increase in the tumor marker MART-1 allowing for better recognition and potentially increased killing by T cells. Local treatment with PH-894 presents a strategy to decrease BRD4 expression and upregulate MART-1 expression to increase immune response to cancer cells while reducing toxicities associated with systemic therapies. This study supports further development of PH-894 for injectable solid tumor indications such as melanoma. The second study demonstrates the effectiveness of PH-894 as an antitumor cytotoxic agent. The addition of PH-894 to cells in vitro elicited concentration-associated apoptosis of all human cancer cell lines tested, including head and neck squamous cell carcinoma, hepatocellular carcinoma, breast cancer, lung cancer, glioblastoma, melanoma, colon cancer, ovarian cancer, and cervical cancer.

07:22 EDT AstraZeneca announces first data from four pivotal Phase III trials at ESMO - The company states: "AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its robust portfolio and pipeline at the European Society for Medical Oncology Congress, 20 to 24 October 2023. Nearly 100 abstracts will feature 19 approved and potential new medicines from AstraZeneca including two late-breaking Presidential Symposia and 26 oral presentations. Highlights include: TROPION-Lung01 Phase III trial of AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC) (Presidential Symposium, Monday 23 October). TROPION-Breast01 Phase III trial of datopotamab deruxtecan in patients with previously treated inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer (Presidential Symposium, Monday 23 October). FLAURA2 Phase III trial of Tagrisso (osimertinib) plus chemotherapy in EGFR-mutated (EGFRm) advanced NSCLC including safety and central nervous system metastases outcomes. Results were recently presented from the progression-free survival (PFS) primary analysis. DUO-E Phase III trial of Imfinzi (durvalumab) plus platinum-based chemotherapy followed by either Imfinzi monotherapy or Imfinzi plus Lynparza (olaparib) as maintenance therapy in newly diagnosed advanced or recurrent endometrial cancer. MATTERHORN Phase III trial of Imfinzi plus neoadjuvant chemotherapy (before surgery) for patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. DESTINY-PanTumor02 Phase II trial of AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in previously treated HER2-expressing advanced solid tumours including PFS and overall survival (OS) data from the primary analysis. Three bispecifics: data from several presentations will highlight the Company's robust clinical programme of novel immuno-oncology (IO) bispecific antibodies including data for volrustomig in advanced clear cell renal cell carcinoma (MEDI5752, targeting PD-1/CTLA-4), and data for rilvegostomig (AZD2936, targeting PD-1/TIGIT) and sabestomig (AZD7789, targeting PD-1/TIM3) in lung cancer." Reference Link

07:15 EDT Gritstone announces presentations on next gen COVID-19 vaccine - Gritstone bio announced the presentation of results from three ongoing Phase 1 studies evaluating its self-amplifying mRNA vaccine candidates against COVID-19 at IDWeek 2023, occurring October 11-15, 2023, in Boston, MA. Gritstone will present further follow up data from the CORAL-CEPI and CORAL-BOOST studies. CORAL-CEPI Presentation: Durable Immune Response Induced by Self-amplifying mRNA SARS-CoV-2 Vaccine Candidates in Vaccine-naive HIV Negative and People Living with HIV Populations. Results presented from Group A, B and C demonstrated: All doses were well tolerated in both HIV-negative participants and PLWH irrespective of SARS-CoV-2 serostatus at baseline. High IgG and neutralizing antibody responses were induced and sustained for at least 12 months. CORAL-BOOST Presentation: Durable Immune Response Induced by a Self-amplifying mRNA SARS-CoV-2 Vaccine Candidate in Adults Previously Vaccinated with mRNA or Adenovirus. Results presented from cohorts 1 - 4 demonstrated: Vaccine candidate was well tolerated as a booster regardless of primary vaccination series. Robust, durable binding and high neutralizing antibodies were induced and sustained for up to at least 12 months against SpikeD614G and variants of concern. Broad T cell responses induced against Spike and non-Spike T cell epitopes included in the vaccine. Use of T cell receptor sequencing assays to assess T cell response breadth. CORAL-NIH Presentation: An Interim Report of the Safety, Reactogenicity, and Immunogenicity of a Self-amplifying mRNA COVID-19 Vaccine GRT-R910 as a Booster in Healthy Adults. Results presented from adults across all age groups and dose levels demonstrated: Vaccine candidate was well-tolerated with no safety signals identified. Durable boosting of humoral immune responses to Spike and variants of concern, and high neutralizing antibody responses to at least 6 months were observed for all vaccine groups. Results are consistent across Phase 1 trials of GRT-R910 and similar vaccines.

07:14 EDT Osino Resources completes acquisition of all surface rights at Twin Hills - Osino Resources has completed the acquisition of all of the surface rights for Osino's Twin Hills Gold Project following Osino's acquisition of two farms that encompass the full extent of the mining area for Twin Hills and all related plant infrastructure. The Klein Okawayo farm and the Okawayo farm were acquired for an aggregate purchase price of C$8.8 million plus any relevant taxes, payable in cash and shares of the Company. The Okawayo farmland was acquired directly by Osino's Namibian subsidiary, Osino Farming Investments from Mr. Siegfried Strzelecki pursuant to an agreement dated August 2, 2021 for consideration totalling N$95,000,000 comprised of: cash payment of N$50,000,000; cash payment of N$20,000,000 due on the 12-month anniversary of the June 15, 2023 registration date registering the Purchaser on title of the Okawayo farmland; and N$25,000,000 payable in cash or common shares of the Company, at Osino's discretion and subject to the policies of the TSX Venture Exchange, due on the 24-month anniversary of the registration date. Within 30 days of the First Anniversary Payment, Osino has the option to accelerate the Second Anniversary Payment payable in cash or Shares for a 20% discount amounting to a payment of N$20,000,000. The Purchaser became the registered owner of the Okawayo farm subject to securing the required Namibian regulatory approvals which have now been obtained. The Klein Okawayo farm was acquired indirectly from Mr. Adriann van der Walt and Roselett van der Walt by Osino's Namibian subsidiary, Osino Property Holdings by acquiring 100% ownership of the Namibian company, Klein Okawayo Farming, which owns the Klein Okawayo farm lands free of liabilities pursuant to an agreement dated May 11, 2021 for cash consideration totalling N$26,000,000. Osino Holdings became the registered owner of 100% of Farm Holdco effective as of May 22, 2023, subject to securing the required Namibian regulatory approvals which have now been obtained. To complete the Farm Acquisitions, Osino complied with all regulatory and ministerial requirements including the granting of a Status of Investment Certificate, merger approvals by the Competition Commission of Namibia and the mandatory waivers for the acquisition of agricultural land in Namibia. In addition, all land taxes, duties, and encumbrances on the properties were fully settled prior to closing. Both transactions have now closed in accordance with the terms and conditions as set out in the signed definitive acquisition agreements.

07:10 EDT Axsome Therapeutics appoints Mahony to board of directors - Axsome Therapeutics (AXSM) announced that Susan Mahony, PhD, has been appointed to Axsome's board of directors, effective immediately. Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen (AMGN) in October 2023.

07:09 EDT ZyVersa Therapeutics announces peer-reviewed publication on VAR 200 - ZyVersa Therapeutics announces publication of a paper in the peer-reviewed journal, Nature Reviews Nephrology, that summarizes data highlighting how lipid accumulation in the kidneys contributes to CKD development and disease progression. In the review paper titled, "Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease," the following key points were made: Lipids and lipid-related enzymes have a major role in modulating the function of the kidney's filtration system, and lipid accumulation can drive CKD irrespective of circulating lipid levels and use of systemic lipid lowering drugs like statins. Although several lipid types, including cholesterol, triglycerides, fatty acids, and phospholipids, are dysregulated in the kidney and contribute to CKD progression, dysregulation of cholesterol metabolism is one of the hallmarks of kidney injury in CKD. Cholesterol accumulation occurs in association with impaired transport of cholesterol out of the kidney. Accumulation of fatty acids triggers kidney cell damage by promoting inflammation and fibrosis. The paper includes a brief overview of Cholesterol Efflux Mediator VAR 200, highlighting that it reduced cholesterol accumulation and cell death in podocytes in vitro, and provided protection from kidney disease progression in mouse models of diabetic kidney disease, FSGS, and Alport Syndrome.

07:07 EDT PureTech Health presents data on LYT-100 trial in adults at CHEST - PureTech Health presented clinical data supporting the differentiated profile of LYT-100 or deupirfenidone at the CHEST Annual Meeting in Honolulu, Hawaii. The presentation expands on data from a completed trial of LYT-100 in healthy older adults, which informed the two doses selected for the ongoing, global Phase 2b dose-ranging trial of LYT-100 ELEVATE IPF in patients with idiopathic pulmonary fibrosis, IPF . In addition to supporting the improved tolerability of LYT-100 versus the FDA-approved dose of pirfenidone, the data provide insights into the selection of the higher dose of LYT-100 that is also being evaluated in ELEVATE IPF. The trial showed that a 550 mg dose of LYT-100 given three times daily,TID, provided bioequivalent drug exposure to the FDA-approved dose of pirfenidone, 801 mg TID. LYT-100 also demonstrated a 24% lower peak drug concentration than pirfenidone, which is a key factor generally associated with tolerability. "Our goal with the ELEVATE IPF trial is to validate the ability of LYT-100 to deliver a more tolerable treatment with equivalent efficacy to pirfenidone at one dose while also exploring the potential for enhanced efficacy at a higher dose." "Tolerability is a major challenge with the currently available IPF treatments, and it often results in both temporary and permanent dose reductions, premature discontinuation and a reluctance for patients to even begin treatment," said Dr. Toby Maher, M.D., Ph.D., Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, Los Angeles, who is presenting the poster at CHEST and is an investigator in the ELEVATE IPF trial. "

07:07 EDT PolyPid regains compliance with Nasdaq minimum closing bid price rule - PolyPid announced that it has received a written notice from The Nasdaq Stock Market that the Company has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities, including the Company's ordinary shares, to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company's ordinary shares was at $1.00 per share or greater for the 11 consecutive business days prior to the date of the notice. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), and Nasdaq considers the prior bid price deficiency matter now closed.

07:06 EDT Kazia Therapeutics announces intento to de-list from ASX - Kazia Therapeutics announces its intention to de-list from the Australian Securities Exchange, or ASX. Kazia advises that it has submitted a formal application to the ASX to be removed from the official list of the ASX in accordance with ASX Listing Rule 17.11. This formal request follows the receipt of in-principle advice from the ASX in relation to the proposed Delisting, subject to the satisfaction of the conditions set out below. The Board has ultimately determined that the costs, administrative burden and commercial disadvantages of remaining listed on ASX outweigh any benefits of a continued ASX listing. Following the Delisting, the Company will maintain its listing on the NASDAQ and the fully paid ordinary shares in the Company will no longer be quoted on the ASX. Further details regarding the reasons for and consequences of the Delisting are set out below. Reasons for seeking removal include: Costs; Access to larger equity markets with biotechnology focus; Capital raisings; Location of directors and management. The Company will notify shareholders whose securities are held on the Company's Australian principal share register of the time and date at which the Company will be removed from the Official List shortly.

07:05 EDT Vivid Seats introduces National Fan Day - Vivid Seats announced the creationof National Fan Day a national holiday dedicated to the fans that power the live events we love. The first-ever National Fan Day will take place on October 11th, 2023, and celebrates the kind of fandom that Vivid Seats rewards every day through the only loyalty program in the industry. With Vivid Seats Rewards, fans who buy 10 tickets get their 11th free, and much more. It's clear that fandom has reached new heights in 2023. A new national study* commissioned by Vivid Seats, and conducted by global market research firm, The Harris Poll reveals just how dedicated Americans are when it comes to their favorite sports teams, artists, and bands.

07:04 EDT Humana names Jim Rechtin COO, to succeed Bruce Broussard as CEO in 2024 - Humana announced it has named health care industry veteran Jim Rechtin as president and COO of Humana, effective January 8, 2024, as part of a long-planned CEO transition. He will report to Bruce Broussard, CEO, until the latter half of 2024 at which time Broussard will step down and Rechtin will assume the CEO role. Broussard joined Humana in 2011 and assumed the role of CEO in 2013. Rechtin will lead Humana into its next chapter as part of a multi-year succession plan, with Broussard to remain as a strategic advisor to the company into 2025.

07:02 EDT SaverOne 2014 says no disruption to business operations in Israel - SaverOne 2014 addressed the status of the company's continued and uninterrupted activity in Israel, against the background of the recent terrorist attack in the south of the country and the subsequent declaration of war by the Israeli government against the Hamas terrorist organization. SaverOne's management affirms that the company has not seen any impact to its ongoing operations in Israel and continues to work as normal. At the same time, the company continues to monitor its ongoing activities and make any needed adjustments to ensure a smooth continuity of its business, while supporting the safety and well-being of its employees. Furthermore, the company notes that its headquarters are in the center of the country, north-east of Tel Aviv and not near any borders. Ori Gilboa, CEO of SaverOne, commented, "We are absolutely devastated by the horrific attacks against our people over the past weekend. We pray for the victims as well as their families, friends and loved ones. We are resilient, and as we have done many times in the past, we will overcome these challenging times. I reaffirm to our employees, partners and shareholders that our continued operations have not been impacted in Israel and we continue to fulfill our duties and service our customers and partners, as normal, and to the fullest of our abilities. Finally, I would like to thank all those that have reached out to express their support and best wishes. "

06:52 EDT Endeavour Silver reports Q3 production 1.14M silver oz and 9,089 gold oz - Endeavour Silver reports Q3 production of 1,148,735 silver ounces, or oz, and 9,089 gold oz, for silver equivalent, or AgEq, production of 1.9M oz. Production continues to track in-line with the 2023 production guidance of 8.6-9.5M silver equivalent ounces, totaling 6.5 million AgEq oz for the nine months ended September 30. "Our production decreased this quarter compared to previous quarters due to lower throughput and ore grades processed at Guanacevi. We mined lower grades due to mine sequencing changes related to access and ventilation, whereas throughput was impacted due to an extended scheduled maintenance program. The mine sequencing is now back to plan, which will result in access to improved ore grades going forward. Additionally, the maintenance program has been executed successfully to minimize operational risks in the mill," stated Dan Dickson, CEO. "We anticipate improved operational performance and operational efficiency in the last quarter."

06:46 EDT Lazard reports preliminary AUM $228.3B as of September 30 - Lazard reported that its preliminary assets under management as of September 30, 2023 totaled approximately $228.3B. The month's AUM included market depreciation of $5.9B, foreign exchange depreciation of $2.7B and net outflows of $0.5B. Preliminary average assets under management for the quarter ended September 30, 2023 were $236.3B.

06:38 EDT CGI Inc. to acquire Momentum Consulting, terms undisclosed - CGI announced the acquisition of Momentum Consulting. Momentum Consulting, a Florida-approved vendor and minority-owned business founded in 2002, brings more than 175 consultants to CGI as well as client relationships in retail, manufacturing, transportation, and logistics.

06:32 EDT Exxon Mobil to acquire Pioneer Natural for $253 per share, or $59.5B - Exxon Mobil (XOM) and Pioneer Natural Resources (PXD) jointly announced a definitive agreement for ExxonMobil to acquire Pioneer. The merger is an all-stock transaction valued at $59.5B, or $253 per share, based on ExxonMobil's closing price on October 5, 2023. Under the terms of the agreement, Pioneer shareholders will receive 2.3234 shares of ExxonMobil for each Pioneer share at closing. The implied total enterprise value of the transaction, including net debt, is approximately $64.5B. The per-share merger consideration noted above represents an approximate 18% premium to Pioneer's undisturbed closing price on October 5 and a 9% premium to its prior 30-day volume-weighted average price on the same day. The Boards of Directors of both companies have unanimously approved the transaction, which is subject to customary regulatory reviews and approvals. It is also subject to approval by Pioneer shareholders. The transaction is expected to close in the first half of 2024.

06:09 EDT GSK confirms confidential settlement reached in Cantlay/Harper Zantac case - GSK plc confirmed it has reached a confidential settlement in the Cantlay/Harper case filed in California state court. "The case, which was set to begin trial on 13 November 2023, will be dismissed. The company has also settled the three remaining breast cancer bellwether cases in California. GSK will be dismissed from these cases, removing all related pre-trial hearings for the company. The settlements reflect the company's desire to avoid the distraction related to protracted litigation. GSK does not admit any liability in the settlements and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases," GSK stated in a press release issued today by GSK to the London Stock Exchange.

06:02 EDT KBR announces K-GreeN technology selected by adoqua Power2X - KBR announced that its K-GreeN technology has been selected by Madoqua Power2X, a joint venture of Madoqua Renewables, Power2X and Copenhagen Infrastructure Partners, for Madoqua's green ammonia project at Sines Industrial Zone in Portugal. Under the terms of the contract, KBR will provide technology license, proprietary engineering design and equipment, and catalyst solutions to Madoqua for its green ammonia projects, including 1200 tonnes per day in Phase 1 and 1500 tonnes per day in Phase 2. Additionally, Madoqua will implement KBR's suite of advanced digital solutions to optimize the operations and energy efficiency for the facility.

06:01 EDT BioCardia completes enrollment in Phase III CardiAMP HF trial - BioCardia announces completion of enrollment in its CardiAMP Heart Failure Trial and initiation of a discussion with the FDA on a second pivotal study protocol adapted for the responders in the initial trial with the objective of gaining FDA marketing approval. As previously disclosed, interim trial results reviewed by the Data Safety Monitoring Board in July 2023 indicated that the Phase III CardiAMP Heart Failure trial is not likely to meet the primary endpoint for efficacy at 12 months, in part, because both study groups of randomized patients have had good outcomes. There were no treatment emergent safety concerns by the DSMB. Notably, patients receiving CardiAMP Cell Therapy followed up to 24 months showed a 37% relative risk reduction of cardiac death equivalents and an 18% relative risk reduction in major adverse cardiac and cerebrovascular events.

05:56 EDT Walgreens Boots Alliance appoints Tim Wentworth as CEO - Walgreens Boots Alliance (WBA) announced the appointment of Tim Wentworth as the company's new CEO, effective on October 23. Wentworth will also join the WBA board of directors upon assuming the role. Most recently, as founding CEO of Evernorth, Cigna's (CI) health services organization that partners with health plans, employers and government organizations, Wentworth brought together health service capabilities including care provision, pharmacy solutions and benefits management.

05:51 EDT Genentech announces CHIMES trial results - Genentech, a member of Roche, announced results from the Phase IV CHIMES trial evaluating Ocrevus in Black and Hispanic / Latinx people with relapsing multiple sclerosis, or MS. One-year data from the trial show that Ocrevus effectively manages MS disease activity in these populations. Approximately half of all trial participants achieved no evidence of disease activity, or NEDA, at week 48, with over 94% of participants experiencing no relapses during this period. The safety and efficacy profile demonstrated in the trial was consistent with the large body of clinical evidence from other Ocrevus studies. The results were presented at the 9th Joint ECTRIMS-ACTRIMS Meeting in Milan. Additional results from the CHIMES trial showed more than 90% of trial participants had no 24-week confirmed disability progression and no T1-Gd+ lesions. During the trial period, no new or enlarging T2 lesions were observed in about half of Black participants and more than half of Hispanic / Latinx participants. No new safety signals were reported.

05:44 EDT Caledonia Mining reports Blanket gold Mine production 21,772 ounces - Caledonia Mining announced gold production from the Blanket Mine in Zimbabwe for the quarter ended September 30. All production numbers are expressed on a 100% basis and are based on the final assay at the refiners. Reports quarterly gold production of 21,772 ounces, a new quarterly record for Blanket mine. Reports an increase of 3% on the 21,120 ounces produced in the corresponding quarter of 2022. Gold produced in the nine months to the end of September was 55,244 ounces. Caledonia reiterates its gold production guidance for 2023 of between 75,000 and 80,000 ounces.

05:38 EDT Bristol Myers announces new Zeposia data on long term disease progression - Bristol Myers announced new data showing that after eight years of follow-up, 76% of patients treated with Zeposia for relapsing multiple sclerosis, or RMS, were free of six-month confirmed disability progression, or CDP. Findings also demonstrated treatment with Zeposia resulted in low rates of progression independent relapse activity, or PIRA, and relapse-associated worsening, or RAW, key drivers of disease progression and permanent disability in multiple sclerosis. In all participants, PIRA and RAW were observed in 13.2% and 10.7% of participants treated with continuous Zeposia, respectively, after eight years in the open-label extension study. Higher baseline expanded disability status scale, or EDSS, scores to assess CDP and lower baseline whole brain, cortical grey matter and thalamic volumes were predictive of RAW but not PIRA. The new late-breaking data will be presented on October 11 at the 9th Joint ECTRIMS-ACTRIMS meeting taking place in Milan, Italy. The analyses of PIRA and RAW included 363 patients who received continuous Zeposia treatment in the Phase 3 DAYBREAK open-label extension trial, following completion of the Phase 3 RADIANCE trial. Among patients with CDP, 54.5% and 44.3% had PIRA or RAW, respectively, and 8% had both. The Phase 3b ENLIGHTEN study is a trial evaluating patients with early RMS, the majority of whom have not received disease modifying therapies. Interim ad hoc data showed that after one year of Zeposia treatment, almost half of patients living with early RMS showed clinically meaningful improvement in cognitive functioning, defined as an increase of at least four points or 10% from baseline as measured by the symbol digital modalities test; 25.9% remained stable in their cognitive function as evidenced by a plus or minus four points or 10% change in SDMT versus baseline; and 26.7% worsened as evidenced by a decrease of at least four points or 10% in SDMT versus baseline. Additionally, ENLIGHTEN participants had little clinical or radiologic evidence of RMS disease activity during that year, with 91.9% of patients free of gadolinium-enhancing lesions at Month 12. Treatment-emergent adverse events, or TEAEs, were assessed from the start of the ENLIGHTEN trial through the data cutoff and showed that COVID-19 was the most frequent TEAE, with other common TEAEs largely consistent with those reported in the overall Zeposia clinical development program.

05:31 EDT Bentley Systems subsidiary to acquire Flow State Solutions, terms undisclosed - Bentley Systems announced that Seequent, The Bentley Subsurface company, has signed an agreement to acquire Flow State Solutions. The move further solidifies Seequent's position as the most comprehensive subsurface software provider for the geothermal industry.

05:23 EDT Snail, Angela Game settle Myth of Empires trade secret and copyright allegations - Snail along with its subsidiary Studio Wildcard, has officially disclosed a settlement agreement with Suzhou Angela Online Game Technology and Imperium Interactive Entertainment. The settlement marks the resolution of copyright and trade secret litigation concerning Myth of Empires, or MoE, and includes ongoing royalty payments of Myth of Empires from Angela to Snail, while Snail assists the distribution of Myth of Empires. While details of the settlement and release agreement remain confidential, the parties jointly announced the resolution of their disputes and Snail Games' cooperation with Angela in the distribution of Myth of Empires going forward. This is pursuant to the terms of the settlement, Snail Games will withdraw its DMCA Notice against Myth of Empires and work collaboratively with PC distribution platforms for a re-release of the game in early 2024. Additionally, Snail Games will partner on the global launch of MoE on both PlayStation and Microsoft platforms in early 2024 and will assist in public relations, marketing, and first party support for the game. Myth of Empires will be released by Angela and Snail Games both physically and digitally on console and PC. Angela Games will also develop a steady cadence of DLC and expansion packs for Myth of Empires, in partnership with Snail Games USA.

05:08 EDT Himax commences mass production of LTDI automotive display solution in Q3 - Himax announced that mass production of its Large Touch and Display Driver Integration, or LTDI, automotive display solution, HX83180 series, for vendors' latest NEV models, commenced during the third quarter of 2023. LTDI design is particularly suitable for prevailing NEVs, known for their stylish smart cabins that feature large-sized display, panoramic view, free-form, curved design and in-cell touch functions. The company has received a proliferation of inquiries regarding its LTDI solution which is now universally adopted by panel makers across the board. The advancement of electric and autonomous vehicles has shifted the focus of the automotive industry from traditional metrics of engine efficiency and horsepower to prioritizing battery longevity and user-friendly interior cabin design. With the introduction of innovative display technology, car manufacturers have redefined the functionality of dashboards and central consoles, transforming them into an integrated, panoramic cockpit display with touch features. This transformative approach provides a consumer-electronics-inspired human-machine interface, delivering a futuristic and high-tech driving experience.